Overview
What is International Aids Vaccine Initiative Inc?
International Aids Vaccine Initiative Inc is a nonprofit scientific research organization based in New York, dedicated to developing vaccines and antibodies, primarily for HIV and other infectious diseases, in Africa, India, Europe, and the U.S. Their mission involves fostering collaborations among various sectors to explore innovative approaches to public health threats that disproportionately affect people living in poverty. Through rigorous clinical evaluations, IAVI advances vaccine and antibody candidates to establish their safety and efficacy, strengthening healthcare infrastructure and scientific capacity in partner countries. To date, they have conducted over 50 epidemiological studies, providing voluntary HIV testing, counseling services, and healthcare referrals to hundreds of thousands of individuals in Africa. IAVI's research is conducted with the highest scientific and ethical standards, and they have launched research consortia to address major scientific problems in biomedical product development. A significant portion of their work is conducted in developing countries where the need for infectious disease prevention is greatest.
Official website here: www.iavi.org
Is International Aids Vaccine Initiative Inc legitimate?
International Aids Vaccine Initiative Inc is a legitimate nonprofit organization registered as a 501(c)(3) entity. International Aids Vaccine Initiative Inc submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.
Here are some key statistics you may want to consider:
Executive Compensation: $2,614,665
Professional Fundraising Fees: $0
Other Salaries and Wages: $33,612,789
For more financial information, click here
Official website here: www.iavi.org
What is the mission statement of International Aids Vaccine Initiative Inc?
The International Aids Vaccine Initiative Inc is a nonprofit scientific research organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Through research and clinical trials in Africa, India, Europe, and the US, the organization advances scientific discoveries and seeks to accelerate the introduction of affordable, globally accessible public health solutions in low-income countries. IAVI fosters unique collaborations among academia, industry, local communities, governments, and funders to explore new ways to address public health threats that disproportionately affect people living in poverty. The organization puts vaccine and antibody candidates through rigorous clinical evaluation to establish their safety and efficacy, strengthening healthcare infrastructure and scientific capacity in partner countries. To date, IAVI and its partners have advanced dozens of HIV vaccine candidates into early stage clinical trials and conducted more than 50 epidemiological studies, providing voluntary HIV testing, counseling services, and healthcare referrals to over 870,000 individuals in Africa. IAVI supports preclinical development and clinical testing of vaccine candidates and antibodies for various diseases, including tuberculosis, Lassa fever, Marburg, Ebola Sudan, and COVID-19.
Official website here: www.iavi.org
Who is the CEO of International Aids Vaccine Initiative Inc?
Mark B Feinberg is the President/Ceo of International Aids Vaccine Initiative Inc. The CEO's salary of International Aids Vaccine Initiative Inc is $666,687 and their total compensation is $763,253.
Official website here: www.iavi.org
What is the revenue of International Aids Vaccine Initiative Inc?
International Aids Vaccine Initiative Inc's revenue in 2022 was $146,782,280.
Official website here: www.iavi.org
Who are the executives of International Aids Vaccine Initiative Inc and what are their salaries?
The average compensation at International Aids Vaccine Initiative Inc during 2022 was $147,867. There are 245 employees and 14 volunteers at International Aids Vaccine Initiative Inc.
Here are 24 key members and their salaries (International Aids Vaccine Initiative Inc's CEO's salary is $666,687 and their total compensation is $763,253):
- Mark B Feinberg (President/Ceo) [Trustee/Director]
- Ana Cespedes Montoya (Chief Operating Officer)
- Swati Gupta (Vp, Head Of Eid & Epidemiology)
- Louis D Schwartz (Asst. Sec. & Chief Financial Officer)
- Thomas Hassell (Vp, Pdc (Until 9/30/22))
- Dagna Laufer (Vp & Head Of Clinical Development)
- Christopher Parks - Assoc (Vp, Viral Vaccines & Head Of The Ddl)
- Min Ding (Gen. Couns. & Sec. (From 3/14/22))
- Frances Sinha (Cpo, Vp Of Hr (Until 12/1/22))
- Eric Skjeveland (Vp, Business Development)
- Eric Paul Goosby (Board Chair) [Trustee/Director]
- Robert Goldberg (Board Treasurer) [Trustee/Director]
- Linda-Gail Becker (Board Member) [Trustee/Director]
- David Blumberg (Board Member) [Trustee/Director]
- Jim Connolly (Board Member) [Trustee/Director]
- Mark Dybul (Board Member) [Trustee/Director]
- Wafaa El-Sadr (Board Member) [Trustee/Director]
- John Nkengasong (Board Member (Until 5/16/22)) [Trustee/Director]
- Alexis M Pinto (Board Member) [Trustee/Director]
- John W Shiver (Board Member) [Trustee/Director]
- Susan Silbermann (Board Member) [Trustee/Director]
- Anne Martin Simonds (Board Member) [Trustee/Director]
- Rajeev Venkayya (Board Member) [Trustee/Director]
- Marijke Wijnroks (Board Member) [Trustee/Director]
Official website here: www.iavi.org
Where can I find the form 990 for International Aids Vaccine Initiative Inc?
The International Aids Vaccine Initiative Inc’s most recent form 990 was submitted in 2022 and can be accessed here
Official website here: www.iavi.org
Learn more at the official website: www.iavi.org
Mission Statement of International Aids Vaccine Initiative Inc
International Aids Vaccine Initiative Inc, a nonprofit scientific research organization, is dedicated to translating scientific discoveries into affordable and globally accessible public health solutions. Their mission is to develop vaccines and antibodies for HIV, tuberculosis, emerging infectious diseases, and neglected diseases.
IAVI conducts scientific and clinical research in Africa, India, Europe, and the United States to advance vaccine and antibody candidates for the developing world. By fostering unique collaborations among academia, industry, local communities, governments, and funders, IAVI explores new ways to tackle public health threats that disproportionately affect people living in poverty.
IAVI's rigorous process of clinical evaluation among key populations establishes the safety and efficacy of their candidates, strengthening the healthcare infrastructure and scientific capacity of countries where they operate. To date, IAVI and its partners have advanced dozens of HIV vaccine candidates into early stage clinical trials, with one recently yielding promising results. IAVI has also conducted more than 50 epidemiological studies and provided voluntary HIV testing, counseling services, and healthcare referrals to over 870,000 individuals in Africa.
Beyond HIV, IAVI supports preclinical development and clinical testing of vaccine candidates for other diseases, including tuberculosis, Lassa fever, Marburg, Ebola Sudan, and COVID-19, as well as antibody candidates for disease prevention and treatment. IAVI's trials adhere to the highest scientific and ethical standards to protect the rights, well-being, and dignity of trial volunteers. IAVI has also launched research consortia to address major scientific problems of biomedical product development. A significant portion of the research IAVI supports is conducted in developing countries where the need for infectious disease prevention is greatest. IAVI also supports external researchers by providing technical and scientific expertise to accelerate the development of their own products.
Impact
This information is meant to be a general summary of International Aids Vaccine Initiative Inc. Please take the time to review official sources before making any decisions based upon the content provided here.
Thursday, August 15, 2024
International AIDS Vaccine Initiative Inc's impact is significant in the global fight against HIV, tuberculosis, emerging infectious diseases, and neglected diseases. Through its research and development efforts across multiple continents, including Africa, India, Europe, and the U.S., IAVI is translating scientific discoveries into affordable and accessible public health solutions.
IAVI has advanced numerous HIV vaccine candidates into early-stage clinical trials, with promising results that offer hope for an effective vaccine against HIV. The organization has conducted groundbreaking HIV vaccine trials in sub-Saharan countries, where the disease burden is the highest, and has also tested mRNA HIV vaccine candidates in Africa. In addition to HIV, IAVI supports research and clinical testing for other diseases such as tuberculosis, Lassa fever, Marburg, Ebola Sudan, and COVID-19.
Furthermore, IAVI has conducted over 50 epidemiological studies and provided voluntary HIV testing, counseling services, and healthcare referrals to over 870,000 individuals in Africa. The organization upholds the highest scientific and ethical standards in its clinical trials to safeguard the rights, well-being, and dignity of trial volunteers. Through collaborations with academia, industry, local communities, governments, and funders, IAVI is strengthening healthcare infrastructure and scientific capacity in countries where it operates.
Overall, International AIDS Vaccine Initiative Inc plays a crucial role in advancing scientific discovery, developing vaccines and antibodies, and addressing public health threats that disproportionately affect marginalized populations. Its efforts have the potential to make a lasting impact on global health outcomes and disease prevention strategies.
Financials
This financial information is from Propublica.
Other financial information:
This information is from the most recently submitted tax form from this organization, which was in 2022.
- Assets and Liabilities:
Programs
Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.
CONTRACT SERVICE FEES
Revenue
$2,569,928
Organization Details
Founding Year
1996
Phone
(212) 847-1111
Principal Officer
Mark B Feinberg
Main Address
125 BROAD STREET 9TH FL, NEW YORK, NY, 10004
Website
www.iavi.org
NTEE Category
Code: Q30 - International
If you are a representative of International Aids Vaccine Initiative Inc and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.